Patents by Inventor Toshizumi Tanabe
Toshizumi Tanabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10697004Abstract: A method in which a mutant gene present in a gene pool mixedly with a large number of wild-type genes can be simply, inexpensively and sensitively detected is developed and provided. A clamping probe that is connected to a target nucleic acid molecule in two regions of first and second target nucleic acid complementary regions so that a wild-type target nucleic acid molecule and a mutant-type target nucleic acid molecule can be distinguished from each other depending on a difference in complementarity to these target nucleic acid molecules is provided.Type: GrantFiled: November 6, 2015Date of Patent: June 30, 2020Assignee: Osaka City UniversityInventors: Akira Tachibana, Toshizumi Tanabe
-
Publication number: 20170356033Abstract: A method in which a mutant gene present in a gene pool mixedly with a large number of wild-type genes can be simply, inexpensively and sensitively detected is developed and provided. A clamping probe that is connected to a target nucleic acid molecule in two regions of first and second target nucleic acid complementary regions so that a wild-type target nucleic acid molecule and a mutant-type target nucleic acid molecule can be distinguished from each other depending on a difference in complementarity to these target nucleic acid molecules is provided.Type: ApplicationFiled: November 6, 2015Publication date: December 14, 2017Applicant: Osaka City UniversityInventors: Akira Tachibana, Toshizumi Tanabe
-
Patent number: 9593331Abstract: Provided are an improved double-stranded nucleic acid molecule involved in gene expression control mediated by a gene silencing mechanism, a method of producing the molecule, and a pharmaceutical composition comprising the double-stranded nucleic acid molecule. The double-stranded nucleic acid molecule for gene expression control comprises an antisense strand having a length of 18 to 28 nucleotides and a sense strand including a complementary moiety composed of a sequence sufficiently complementary to the antisense strand and a protruding single-stranded 5?-end moiety having a length of 2 to 100 nucleotides. The sense strand and the antisense strand form base pairs via the complementary moiety. The method produces such a double-stranded nucleic acid molecule, and the pharmaceutical composition contains such a double-stranded nucleic acid molecule as an active ingredient.Type: GrantFiled: November 1, 2012Date of Patent: March 14, 2017Assignee: Osaka City UniversityInventors: Akira Tachibana, Toshizumi Tanabe
-
Publication number: 20160222386Abstract: The purpose of the present invention is to develop and provide a nucleic acid molecule that can specifically and efficiently inhibit the activity of a target RNAi molecule and can be produced safely at a low cost. Provided is a nucleic acid molecule for inhibiting the activity of a target RNAi molecule. The nucleic acid molecule comprises a single-stranded nucleic acid moiety that contains one unmodified DNA region composed of a nucleotide sequence completely or sufficiently complementary to a nucleotide sequence of a functional strand having the activity in the target RNAi molecule and a double-stranded nucleic acid moiety to be linked to at least one of the 5?-end and the 3?-end of the single-stranded nucleic acid moiety.Type: ApplicationFiled: April 22, 2016Publication date: August 4, 2016Applicant: Osaka City UniversityInventors: Akira Tachibana, Toshizumi Tanabe
-
Publication number: 20150011745Abstract: The purpose of the present invention is to develop and provide a nucleic acid molecule that can specifically and efficiently inhibit the activity of a target RNAi molecule and can be produced safely at a low cost. Provided is a nucleic acid molecule for inhibiting the activity of a target RNAi molecule. The nucleic acid molecule comprises a single-stranded nucleic acid moiety that contains one unmodified DNA region composed of a nucleotide sequence completely or sufficiently complementary to a nucleotide sequence of a functional strand having the activity in the target RNAi molecule and a double-stranded nucleic acid moiety to be linked to at least one of the 5?-end and the 3?-end of the single-stranded nucleic acid moiety.Type: ApplicationFiled: November 14, 2012Publication date: January 8, 2015Applicant: Osaka City UniversityInventors: Akira Tachibana, Toshizumi Tanabe
-
Publication number: 20140315982Abstract: Provided are an improved double-stranded nucleic acid molecule involved in gene expression control mediated by a gene silencing mechanism, a method of producing the molecule, and a pharmaceutical composition comprising the double-stranded nucleic acid molecule. The double-stranded nucleic acid molecule for gene expression control comprises an antisense strand having a length of 18 to 28 nucleotides and a sense strand including a complementary moiety composed of a sequence sufficiently complementary to the antisense strand and a protruding single-stranded 5?-end moiety having a length of 2 to 100 nucleotides. The sense strand and the antisense strand form base pairs via the complementary moiety. The method produces such a double-stranded nucleic acid molecule, and the pharmaceutical composition contains such a double-stranded nucleic acid molecule as an active ingredient.Type: ApplicationFiled: November 1, 2012Publication date: October 23, 2014Applicant: Osaka City UniversityInventors: Akira Tachibana, Toshizumi Tanabe
-
Patent number: 5389538Abstract: A mutant human prourokinase wherein a neutral amino acid in the epidermal growth factor (EGF) region of human prourokinase (human PUK) has been replaced with a basic amino acid, or an acidic amino acid has been replaced with a non-acidic amino acid, and a method for producing a mutant human PUK which comprises expression of mutant human PUK by cultivating a host transformed by a plasmid inserted with a DNA sequence coding for said mutant human PUK. By replacing a neutral amino acid in the EGF region of human PUK which is a fibrinolysin with a basic amino acid, or an acidic amino acid with a non-acidic amino acid, half-life in blood can be prolonged, and affinity for fibrin can be improved.Type: GrantFiled: October 6, 1992Date of Patent: February 14, 1995Assignee: The Green Cross CorporationInventors: Toshizumi Tanabe, Masanori Morita, Masaaki Hirose, Yasuo Amatsuji
-
Patent number: 5098840Abstract: A human prourokinase mutant in which the entire or a partial epidermal growth factor domain of human prourokinase is deleted or a partial epidermal growth factor domain of human prourokinase is replaced by one or more different amino acid residues, said mutant having a longer blood half-life than naturally occurring human prourokinase while retaining prourokinase enzymatic activity. In this human prourokinase mutant the region selected from the group consisting of: (a) from asparagine (10) to cysteine (42); (b) from asparagine (10) to aspartic acid (45); and (c) from asparagine (10) to threonine (49) is missing.Type: GrantFiled: May 18, 1990Date of Patent: March 24, 1992Assignee: The Green Cross CorporationInventors: Shunji Kasai, Ryuji Hiramatsu, Shusei Uno, Masanori Nagai, Hirofumi Arimura, Toshizumi Tanabe, Yasuo Amatsuji, Masaaki Hirose, Masanori Morita, Haruhide Kawabe